This Viewpoint explores why biosimilars for chronic diseases, the largest category of biological therapies, are unlikely to yield cost savings.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2qpBkDu
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Abstract BACE1 is an indispensable enzyme for generating β-amyloid peptides, which are excessively accumulated in brains of Alzheimer'...
-
Rhinoplasty is perhaps the most challenging and elegant procedure within all of plastic surgery. In this issue of JAMA Facial Plastic Surger...
-
Publication date: October 2017 Source: International Journal of Biological Macromolecules, Volume 103 Author(s): Sapna, Bijender Singh A...
-
This Viewpoint discusses variances in cardiovascular prevention guidelines from the United States, Europe, and Canada and the debate surroun...
-
Publication date: Available online 3 May 2017 Source: Journal of Dairy Science Author(s): W.A. Knauer, S.M. Godden, A. Dietrich, R.E. Jam...
-
The retina is a specialized sensory organ, which is essential for light detection and visual formation in the human eye. Inherited retinal d...
-
Symptom Presentation and Prescription of Sleep Medications for Veterans With Posttraumatic Stress Disorder. J Nerv Ment Dis. 2017 Jan ...
-
Objectives Oral health inequality in children is a widespread and well-documented problem in oral healthcare. However, objective and reliabl...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου